Otilonium Bromide: Antimuscarinic Agent for Neuroscience and Smooth Muscle Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄) is a highly pure (≥98%) antimuscarinic agent that inhibits acetylcholine receptors to modulate cholinergic signaling in research models (APExBIO). It displays exceptional solubility (≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol) enabling robust experimental workflows. The compound is especially valuable in modeling smooth muscle spasms and gastrointestinal motility disorders due to its validated antispasmodic pharmacology (see comparative analysis). Its stability is optimized at -20°C, and it is intended exclusively for research use, not for diagnostics or therapy. All claims are grounded in peer-reviewed literature and supplier documentation.

Biological Rationale

Otilonium Bromide is classified as an antimuscarinic agent, structurally characterized by a quaternary ammonium moiety that confers high receptor specificity. It acts by competitively inhibiting muscarinic acetylcholine receptors (AChRs), which are central to cholinergic signaling in both the central and peripheral nervous systems (APExBIO). Muscarinic receptors regulate smooth muscle contractility, glandular secretion, and neural transmission. Disruption of these pathways is implicated in gastrointestinal motility disorders and hyperactive smooth muscle states. The use of AChR inhibitors, such as Otilonium Bromide, allows for the precise dissection of cholinergic contributions to physiological and pathophysiological processes in both basic and translational research (see receptor modulation extension).

Mechanism of Action of Otilonium Bromide

Otilonium Bromide exerts its effects by binding to muscarinic acetylcholine receptors on smooth muscle cells, thereby preventing acetylcholine from activating these receptors. This competitive antagonism leads to reduced intracellular calcium mobilization and inhibition of smooth muscle contraction. The compound's quaternary ammonium structure limits its absorption from the gastrointestinal tract, confining its activity primarily to the gut wall (updated solubility and specificity analysis). Its antispasmodic effect is leveraged in experimental models of gastrointestinal motility and cholinergic signaling disorders. In neuroscience, Otilonium Bromide is used to selectively block muscarinic pathways, enabling detailed mapping of receptor-mediated responses (clarifies translational neuroscience protocols).

Evidence & Benchmarks

• Otilonium Bromide demonstrates ≥98% chemical purity under validated supplier protocols (APExBIO).
• Solubility exceeds 28.18 mg/mL in DMSO, 55.8 mg/mL in water, and 91 mg/mL in ethanol at 20–25°C (APExBIO).
• Inhibits muscarinic acetylcholine receptors (AChR) in smooth muscle tissue, reducing contractility in a dose-dependent manner (see clarifies receptor inhibition).
• Stability testing indicates optimal storage at -20°C, with solutions recommended for short-term use to maintain efficacy (APExBIO).
• Models of gastrointestinal motility disorders employ Otilonium Bromide to reproduce smooth muscle spasm and test antispasmodic pharmacology (comparative study).
• Peer-reviewed structural studies on antimuscarinic agents validate the role of muscarinic receptor antagonism in modulating disease phenotypes (Vijayan et al., 2021, DOI:10.1007/s42485-021-00059-w).

Applications, Limits & Misconceptions

Otilonium Bromide is primarily deployed as an AChR inhibitor for neuroscience research and for modeling gastrointestinal motility disorders. Its high solubility and purity enable reproducible receptor modulation in vitro and in situ. The agent is not suitable for diagnostic or therapeutic applications in humans or animals.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not approved for clinical use or direct therapeutic intervention.
• It does not inhibit non-muscarinic receptors or ion channels; its specificity is confined to muscarinic acetylcholine receptors.
• Long-term storage of prepared solutions (>1 week) can reduce efficacy due to degradation.
• Its quaternary structure limits systemic availability; thus, studies of central nervous system effects require direct administration to target tissues.
• Not effective as an antiviral or in viral replication models—distinct from nucleoside analog inhibitors referenced in COVID-19 research (Vijayan et al., 2021).

Workflow Integration & Parameters

Otilonium Bromide (B1607, APExBIO) is supplied as a solid compound. Prepare stock solutions in DMSO, ethanol, or water at concentrations up to the maximum solubility reported (DMSO ≥28.18 mg/mL, water ≥55.8 mg/mL, ethanol ≥91 mg/mL). Store solid at -20°C; keep prepared solutions refrigerated and use within 7 days. For in vitro receptor inhibition, typical working concentrations range from 1–100 μM, depending on cell type and assay sensitivity. Always validate batch purity (≥98%) before use. Integrate into protocols for smooth muscle contractility, cholinergic signaling pathway assays, or gastrointestinal motility disorder modeling. For extended comparative guidance and troubleshooting, refer to this technical resource which outlines protocol optimizations and caveats beyond what is summarized here.

Conclusion & Outlook

Otilonium Bromide is a cornerstone AChR inhibitor for neuroscience and smooth muscle research, offering validated receptor specificity, robust solubility, and high purity. Its established mechanism and workflow guidance support reliable modeling of cholinergic signaling and gastrointestinal motility disorders. Use is strictly limited to research settings; ongoing studies may further define its translational boundaries but clinical application is not supported. For detailed product specifications and ordering, see the APExBIO product page. This article extends and updates the evidence base provided by recent internal and peer-reviewed analyses, clarifying Otilonium Bromide's unique position in experimental pharmacology.